ArticlePathology oncology research : POR2026
Prognostic impact of p53 and HER2 immunohistochemistry profiles in colorectal carcinoma.
Article in Pathology oncology research : POR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a significant health issue worldwide, but represents biologically heterogeneous disease, necessitating improved characterization of molecular and immunophenotypic subgroups. In this retrospective study, we evaluated the prognostic significance and clinicopathological associations of p53 and HER2 expression in 290 surgically resected CRCs. Tissue microarrays from archival formalin-fixed paraffin-embedded samples were analyzed by immunohistochemistry. p53 expression was categorized into wild-type, overexpression, and null patterns, while HER2 was scored according to College of American Pathologists criteria used for gastric carcinoma. Survival analyses were performed using Kaplan-Meier estimates, univariable and multivariable Cox regression, and restricted mean survival time, and immunohistochemical results were correlated with established clinicopathological and molecular features. Neither aberrant p53 expression nor HER2 positivity had a significant impact on 10-year overall survival. The p53 null phenotype showed a significantly increased relative risk of death within 5 years and a significant adverse effect in multivariable Cox regression of 5-year survival adjusted for age. Aberrant p53 expression was significantly associated with left-sided tumor location, mismatch repair proficiency, CK20 positivity, and MUC6 negativity, consistent with the chromosomal instability pathway of CRC. HER2 expression was infrequent and showed no prognostic relevance; however, HER2-positive tumors were significantly associated with CK7 expression, supporting an "extraintestinal" immunophenotypic profile reminiscent of right-sided or non-intestinal differentiation. In conclusion, while p53 and HER2 expression lacked independent prognostic value, their distinct associations with tumor phenotype underscore biologically relevant CRC subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.